ctDNA Reveals Genomic Differences of mRCC During First-, Second-Line Therapy

Video
Conference|ASCO Gastrointestinal Cancer Symposium

This video examines a new study that looked at genomic alterations in the circulating tumor DNA of patients with metastatic RCC during first- and second-line therapies.

In this video, Sumanta K. Pal, MD, of City of Hope in Duarte, California, discusses a study that looked at differences in genomic alterations in the circulating tumor DNA (ctDNA) of patients with metastatic renal cell carcinoma (mRCC) in the first- and second-line treatment setting.

The researchers assessed ctDNA in 224 mRCC patients and found that among those with detected genomic alterations on second-line (56 patients) and first-line (64 patients) therapy, there were differences in TP53 (49% vs 25%, respectively), PIK3CA (17% vs 8%), NF1 (20% vs 15%), and others. Compared with patients still on first-line therapy, differences were even more stark among second-line patients who had previously received anti-VEGF therapy: TP53 (64% vs 31%), PIK3CA (29% vs 8%), and NF1 (29% vs 4%), possibly pointing to mechanisms and pathways of resistance.

The study (abstract 434) was presented at the 2017 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium, held February 16–18 in Orlando, Florida.

Recent Videos
Additional local, regional, or national policy may bolster access to screening for colorectal cancer, according to Aasma Shaukat, MD, MPH.
The mechanism of action for daraxonrasib inhibits effectors and signaling while forming a relatively unstable tri-complex with codon 12 mutations.
Almost all patients evaluable for efficacy reported a decrease in ctDNA when treated with daraxonrasib for RAS-mutant pancreatic ductal adenocarcinoma.
Additional progression-free survival data from the phase 3 BREAKWATER trial will be presented at future meetings.
An expert from the University of California, Los Angeles suggests that the NALIRIFOX may be a beneficial treatment for patients with pancreatic ductal adenocarcinoma.
Patients with metastatic pancreatic ductal adenocarcinoma who receive NALIRIFOX tend to have more gastrointestinal toxicity while nab-paclitaxel/gemcitabine results in more cytopenias, according to an expert from University of California, Los Angeles.
An expert from the University of California, Los Angeles described the purpose and design of the phase 3 NAPOLI-3 study, assessing NALIRIFOX in metastatic pancreatic ductal adenocarcinoma.
An expert from the Mayo Clinic discusses how findings from the ongoing phase 3 MOUNTAINEER trial may enable access to tucatinib, trastuzumab, and chemotherapy in earlier lines of treatment for patients with HER2-positive metastatic colorectal cancer.
Zev A. Wainberg, MD, discusses future research efforts for the treatment of patients with advanced gastric cancer.
Related Content
Integrative Oncology Approaches to Managing Gastrointestinal Cancer

Integrative Oncology Approaches to Managing Gastrointestinal Cancer

Ariana Pelosci
February 4th 2025
Article

Options like acupuncture or cannabis use may be viable to help manage symptoms related to gastrointestinal cancer treatment.

Jun Gong, MD, and Daneng Li, MD, spoke about trials they feel can impact the gastrointestinal space during a CancerNetwork® X Space.

Expert Perspectives on 2024 ASCO GI Cancers Symposium Trial Updates

Jun Gong, MD;Daneng Li, MD
February 19th 2024
Podcast

Jun Gong, MD, and Daneng Li, MD, spoke about trials they feel can impact the gastrointestinal space during a CancerNetwork® X Space.

Atezolizumab and Tremelimumab Combos Yield No Survival Difference in First-Line HCC

Atezolizumab and Tremelimumab Combos Yield No Survival Difference in First-Line HCC

Tim Cortese
January 30th 2025
Article

Atezolizumab and bevacizumab yielded a median OS of 14.0 months vs 14.6 months with tremelimumab followed by durvalumab, a retrospective cohort study found.

Active Surveillance in Small Renal Masses

Active Surveillance in Small Renal Masses

Phillip M. Pierorazio, MD;Ridwan Alam
February 20th 2017
Podcast

In this interview we discuss a new study that looked at the outcomes of patients with small renal masses who were followed with active surveillance.

The major pathologic response rate improved with extended time to surgery using botensilimab plus balstilimab in resectable colorectal cancer.

Neoadjuvant Botensilimab Combo Elicits High MPR Rates in MSS/MSI-H CRC

Roman Fabbricatore
January 27th 2025
Article

The major pathologic response rate improved with extended time to surgery using botensilimab plus balstilimab in resectable colorectal cancer.

Positive Responses Demonstrated by Adagrasib and Cetuximab in KRAS G12C-Mutant mCRC

Positive Responses Demonstrated by Adagrasib and Cetuximab in KRAS G12C-Mutant mCRC

Ashley Chan
January 27th 2025
Article

At a longer follow-up, adagrasib with cetuximab maintained meaningful efficacy and elicited an ORR of 34%, results from the phase 1/2 KRYSTAL-1 showed.